



ASX ANNOUNCEMENT

3 August 2009

Tissue Therapies Lists on the Frankfurt Stock Exchange

Biomedical company, **Tissue Therapies Limited (ASX: TIS)** has announced that it was listed on the Frankfurt Stock Exchange over the weekend, Australian time.

Following recent interest from potential European investors in the clinical trial progress of VitroGro®, the Board of Tissue Therapies has been evaluating the possibility of a listing on a European Exchange to make it more convenient for European investors to trade shares in Tissue Therapies.

To assist with this process, expert advice and was sought from two associated European consulting companies, Dr Reuter Investor Relations and Europe – Australia Investor Relations. The consulting advice of these companies in combination with their European investor contacts has been of significant assistance to the Board of Tissue Therapies, with the Frankfurt listing being achieved as a result. (For more information about both consulting companies, please see below.)

The CEO of Tissue Therapies, Dr Steven Mercer said, “We are grateful to the principals of both consulting companies, Dr Eva Reuter and Mr Trevor Baldock for their expert and experienced advice for the Frankfurt listing and European investor contacts. They have made the listing process very easy for us and have significantly expanded our contact with European investors.”

Dr Mercer also said, “We expect the volume of Tissue Therapies shares traded on the Frankfurt exchange to increase as our VitroGro® results become more widely known in Europe and the resulting increased liquidity to benefit all shareholders.”

Dr. Reuter Investor Relations, the leading German-based consultancy agency, in conjunction with Europe-Australia Investor Relations based in Paris and London, provide highly qualified investor relations services across Europe. The principals provide a unique approach to investor relations services and have extensive personal contacts with Institutional investors in all the main European capitals. The Agency publishes its own analytical material for investors in the Life Sciences and Socially Responsible Investment sectors. The Agency focus is on bringing new shareholders and new capital into client firms.

The company offers its services to a limited number of Australian companies listed on the ASX. For more information please see: www.dr-reuter.eu

Further information: Dr Steven Mercer
CEO, Tissue Therapies Limited
Telephone: +61 (0)7 3839 9938

Email: s.mercer@tissuetherapies.com

About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue repair and various cell culture applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a technology developed by tissue engineering experts at the Institute for Health and Biomedical Innovation at QUT for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, stem cell therapies and other cell culture uses.

Based on its VitroGro® technology, Tissue Therapies is developing more effective medical treatments for wound healing including chronic ulcers and burns,

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: www.tissuetherapies.com